Lineage Cell Therapeutics (original) (raw)
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer.
| Property | Value |
|---|---|
| dbo:abstract | Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical and preclinical programs are in markets with billion dollar opportunities and include five allogeneic (“off-the-shelf”) product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, which is being developed under a worldwide collaboration with Genentech, a member of the Roche Group; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; (iii) VAC2, an allogeneic dendritic cell therapy produced from Lineage's VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer; (iv) ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; and (v) PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage. (en) |
| dbo:foundingYear | 1990-01-01 (xsd:gYear) |
| dbo:industry | dbr:Regenerative_medicine dbr:Biotechnology |
| dbo:location | dbr:Carlsbad,_California |
| dbo:thumbnail | wiki-commons:Special:FilePath/Lineage_Cell_Therapeutics_Updated_Logo.jpeg?width=300 |
| dbo:type | dbr:Public_Company |
| dbo:wikiPageExternalLink | https://lineagecell.com/ |
| dbo:wikiPageID | 40941727 (xsd:integer) |
| dbo:wikiPageLength | 19659 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1122293228 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Cancer_Research_UK dbr:Carlsbad,_California dbr:Roche dbc:1990_establishments_in_California dbc:Biotechnology_companies_of_the_United_States dbr:Genentech dbr:Board_of_directors dbr:California_Institute_for_Regenerative_Medicine dbc:Companies_based_in_Alameda,_California dbr:AgeX_Therapeutics dbr:Regenerative_medicine dbc:Companies_listed_on_NYSE_American dbc:Stem_cells dbr:Biotechnology dbc:Biotechnology_companies_established_in_1990 dbc:Cancer_organizations dbr:Public_Company dbr:Age-related_Macular_Degeneration dbr:Allogeneic |
| dbp:bloomberg | LCTX:US (en) |
| dbp:foundation | 1990 (xsd:integer) |
| dbp:google | LCTX (en) |
| dbp:homepage | https://lineagecell.com/ |
| dbp:industry | dbr:Regenerative_medicine dbr:Biotechnology |
| dbp:keyPeople | Brian Culley, CEO (en) Jill Howe, CFO George A. Samuel III, General Counsel & Corporate Strategy (en) |
| dbp:location | dbr:Carlsbad,_California |
| dbp:logo | File:Lineage_Cell_Therapeutics_Updated_Logo.jpeg (en) |
| dbp:name | Lineage Cell Therapeutics (en) |
| dbp:reuters | LCTX.N (en) |
| dbp:secCik | LCTX (en) |
| dbp:symbol | LCTX (en) |
| dbp:tradedAs | AMEX:LCTX (en) |
| dbp:type | dbr:Public_Company |
| dbp:wikiPageUsesTemplate | dbt:Authority_control dbt:Infobox_company dbt:Reflist dbt:Short_description dbt:Finance_links dbt:TASE |
| dbp:yahoo | LCTX (en) |
| dct:subject | dbc:1990_establishments_in_California dbc:Biotechnology_companies_of_the_United_States dbc:Companies_based_in_Alameda,_California dbc:Companies_listed_on_NYSE_American dbc:Stem_cells dbc:Biotechnology_companies_established_in_1990 dbc:Cancer_organizations |
| rdf:type | owl:Thing dbo:Company schema:Organization dul:Agent dul:SocialPerson dbo:Agent wikidata:Q24229398 wikidata:Q43229 wikidata:Q4830453 dbo:Organisation |
| rdfs:comment | Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. (en) |
| rdfs:label | Lineage Cell Therapeutics (en) |
| owl:sameAs | wikidata:Lineage Cell Therapeutics https://global.dbpedia.org/id/fGqx |
| prov:wasDerivedFrom | wikipedia-en:Lineage_Cell_Therapeutics?oldid=1122293228&ns=0 |
| foaf:depiction | wiki-commons:Special:FilePath/Lineage_Cell_Therapeutics_Updated_Logo.jpeg |
| foaf:homepage | https://lineagecell.com/ |
| foaf:isPrimaryTopicOf | wikipedia-en:Lineage_Cell_Therapeutics |
| is dbo:wikiPageRedirects of | dbr:BioTime dbr:BioTime,_Inc. |
| is dbo:wikiPageWikiLink of | dbr:BioTime dbr:BioTime,_Inc. |
| is foaf:primaryTopic of | wikipedia-en:Lineage_Cell_Therapeutics |
